Skip to main content

Table 2 Molecular characteristics of patients

From: Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up

Characteristics

Patient 1

Patient 2

Patient 3

Patient 4

Patient 5

Patient 6

SNV and INDEL

ARID2 p.A810P

ATM p.H1568D/M900V

CIC p.S721A

ATRX p.R1739*

ATRX p.F2113Sfs*9

BRCA2 p.A2786T

ATRX p.N1283Ifs*63

ATRX p.P842Qfs*27

DNMT3A p.G532S

CHEK2 p.H371Y

FLT4 p.E1336K

ERBB3 p.R488Q

BRCA1 p.G1350S

ERBB2 p.R985H

EPCAM p.Q204H

FGFR4 p.P136L

H3F3A p.G34R

HMCN1 p.I5618T

FAT1 p.Y2690C/S2310C

IDH1 p.R132H

FUBP1 p.Y58Wfs*18

HMCN1 p.R4397Q

KIT p.I744T

IDH1 p.R132H

IDH1 p.R132H

SMARCA4 p.A130T

IDH1 p.R132H

IDH1 p.R132H

MLH1 p.R217C

MYCN p.P44L

IRS2 p.P614L

TP53 p.R273H

NOTCH1 p.F357del

NTRK1 p.D79G

NTRK1 p.H268Q

PDGFRB p.T88I

JAK2 p.E665D

 

PIKCR1 p.K448del

PTCH1 p.T416S

PDGFRA p.S377R

VEGFB p.R77C

KLF4 p.A188E

 

PTCH1 p.E165del

TP53 p.Y234H

PDGFRB p.Q443R

YAP1 p.P335L

NOTCH1 p.D1815G

 

TERT promoter C228T

 

TP53 p.R342*

 

PLCG1 p.E1115K

 

TP53 p.N131del

   

TP53 p.H214R/R175H

     

CNV

CDK6 amp

CCND2 amp

  

CCND2 amp

CDK4 amp

CDKN2A del

CDK4 amp

  

CDK6 amp

PTEN del

CDKN2B del

CDKN2B del

    

MYC amp

MYC amp

    
 

NAB2 amp

    

Chromosomal variation

19q Chr del

  

9p24.3-p21.2 del

7p-q Chr amp

10q11.21-q25.3 del

     

10q26.12-q26.3 del

     

10q26.3 amp

     

11p15.5-p11.12 del

     

12q12-q13.3 del

     

12q14.1-q24.33 del

     

19q Chr del

     

19q11-q12 del

     

19q13.2-q13.43 del

     

21q11.2-q22.3 amp

     

22q11.1-q13.33 del

     

3p26.3-p11.1 del

     

3q11.1-q29 del

     

5p15.33-p12 del

     

5q11.1-q35.3 del

MGMT promoter

Unmethylation

Methylation

Methylation

Unmethylation

Methylation

Unmethylation

MSI

MSS

MSS

MSS

MSS

MSS

MSS

  1. INDEL Small insertion and deletion, MSI Microsatellite instability, MSS Microsatellite stable, SNV Single nucleotide variant